Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

Ibrutinib

d4e0e04e-097f-5f64-99b1-128d16f4ef2f · FDA Approved · targets BTK

Ibrutinib

MeasuredReference

Ibrutinib targets ERBB4_HER4, TXK, BLK. Strongest hallmark effect: tumor promoting inflammation.

Top hallmarks

  • tumor promoting inflammation4.3k
  • evading apoptosis3.3k
  • proliferation3.2k

Top pathways disrupted

  • allograft rejection9.5k
  • apical junction9.5k
  • pi3k akt mtor signaling8.4k

Resistance landscape — Ibrutinib

MeasuredReference

10 known oncogenic variants exist on Ibrutinib's top targets — see detail for inhibition impact.

Open in new tab